Related by context. All words. (Click for frequent words.) 69 HbA1C levels 69 prospectively defined 68 achieved statistical significance 68 MMSE score 67 pCR 67 microbiologically evaluable 67 postintervention 67 venlafaxine XR 67 Hb A1C 66 morphometric vertebral fractures 66 serum urate 66 HIV HCV coinfected 66 ADCS CGIC 66 baseline HbA1c 66 hemoglobin A1c levels 66 β blockers 66 albumin excretion 66 cranial irradiation 66 relapsed MM 66 leukocyte count 66 serum lipid levels 65 HbA 1c levels 65 lipid lowering medications 65 CI -#.# 65 reach statistical significance 65 HER2 expression 65 maximal doses 65 prospectively stratified 65 tipranavir r 65 adenoma recurrence 65 CR nPR 65 octreotide LAR 65 poor metabolizers 65 tumor histology 65 clomipramine 64 VaD 64 KRAS mutations occur 64 colorectal adenoma 64 recurrent venous thromboembolism 64 SIMPADICO 64 symptomatic intracerebral hemorrhage 64 6MWD 64 cerebral oxygenation 64 anagrelide 64 carotid IMT 64 FDA defined valvulopathy 64 echocardiographic parameters 64 BMI z 64 tapentadol ER 64 IOP lowering 64 methotrexate monotherapy 64 LV dysfunction 64 limiting generalizability 64 ICD therapy 64 SGRQ 64 posttreatment 64 corrected QT interval 64 psychiatric comorbidity 64 bezafibrate 64 multivariable adjusted 64 statistical significance p 64 endometrial thickness 64 ARB telmisartan 64 genotypic resistance 64 intact parathyroid hormone 64 Y BOCS 63 pyridostigmine 63 rhGH 63 serum lipid 63 oxycodone CR 63 #mg/day [001] 63 multivariable analysis 63 intravenous cyclophosphamide 63 prognostic indicators 63 MELD scores 63 ziprasidone 63 oral prednisolone 63 non squamous histology 63 glycated hemoglobin levels 63 polytherapy 63 abacavir lamivudine 63 serum LDL cholesterol 63 ACCORD Lipid 63 systolic dysfunction 63 clinically evaluable 63 hip BMD 63 hemoglobin A1c HbA1c 63 SSRI citalopram 63 avosentan 63 rimonabant #mg 63 statistically significant p = 63 corticosteroid dose 63 antibody titer 63 irbesartan 63 preoperative PSA 63 atheroma volume 63 serum urate levels 63 postoperative AF 63 HOMA IR 63 salmeterol fluticasone 63 certolizumab 63 lowest tertile 63 PASI scores 63 severe hypoglycaemia 63 oxcarbazepine 63 serum phosphate levels 63 oocytes retrieved 63 WOMAC pain 63 #.#/#.# mmHg [001] 63 Breslow thickness 63 intima media thickness 63 isolated systolic hypertension 63 estimated GFR 63 multivariate adjustment 63 mutated K ras 63 hematopoietic cancers 63 CC genotype 63 % CI #.#-#.# [008] 63 nondiabetic patients 63 plasma leptin 63 maximally tolerated dose 63 lipid lowering therapy 63 analgesic medications 63 neutrophil counts 63 noninferiority 62 NNT = 62 dose Iluvien 62 HbA1C 62 atorvastatin #mg 62 A1c levels 62 dosing cohort 62 oral anticoagulation 62 inflammatory biomarkers 62 hMG 62 AChE inhibitors 62 MMSE scores 62 undetectable viral 62 GH deficiency 62 eplerenone 62 tertile 62 serum estradiol 62 plasma folate 62 opioid naïve 62 TT genotype 62 nicardipine 62 histologic subtype 62 euthymic patients 62 lipid lowering agents 62 elevated ALT 62 adjunctive placebo 62 beta carotene supplementation 62 fasting triglyceride levels 62 fructosamine 62 metformin monotherapy 62 DAS# CRP 62 NPH insulin 62 NYHA functional class 62 p = .# [002] 62 plasma triglycerides 62 hormone receptor negative 62 Baseline characteristics 62 microbiological eradication 62 plasma pharmacokinetics 62 PSA nadir 62 % Confidence Interval 62 antioxidant supplementation 62 4mg/kg 62 serum concentrations 62 conditional logistic regression 62 insulin detemir 62 nonvertebral fracture 62 CYP#D# inhibitor 62 subsyndromal 62 diastolic pressures 62 definite stent thrombosis 62 moderately emetogenic 62 achieved ACR# 62 left ventricular diastolic 62 complete cytogenetic response 62 receiving ISENTRESS 62 serum PTH 62 Primary endpoints 62 methacholine challenge 62 gadobutrol 62 efficacy evaluable 62 p = #.# [003] 62 NIHSS score 62 ADAS cog 62 creatinine ratio 62 achieve statistical significance 62 REMINYL ® 62 thyrotropin levels 62 chlorthalidone 62 arterial thickening 62 antidiabetic medications 62 liver metastasis 62 NIH CPSI 62 euthyroid 62 glomerular filtration 62 INVEGA ® 62 paricalcitol 62 thiazide diuretics 62 antiretroviral naive 62 antiretroviral naïve 62 MoxDuo TM IR 62 neurocognitive function 62 dalteparin 62 PANSS scores 62 neurologic progression 62 lamotrigine 62 mL/min/#.# m 2 61 ADAS Cog 61 multivariate analyzes 61 urinary cortisol 61 Secondary endpoints included 61 carotid artery thickness 61 antiarrhythmic drug 61 severe exacerbations 61 alteplase 61 treat NNT 61 overt nephropathy 61 postprocedure 61 thrombocytopenic 61 intravesical therapy 61 selenium supplementation 61 hemoglobin concentration 61 μmol L 61 CHD mortality 61 desvenlafaxine succinate 61 BENICAR HCT 61 normotensive 61 Secondary endpoints include 61 CORE OM 61 periprocedural MI 61 CVD mortality 61 eszopiclone 61 mm ³ 61 neurodevelopmental impairment 61 MADRS score 61 daytime alertness 61 timepoints 61 FOLFIRI alone 61 % CI #.#-#.# [003] 61 serum calcium 61 homocysteine concentrations 61 moderate renal impairment 61 autonomic dysfunction 61 serum IGF 61 ejection fractions 61 haematologic 61 univariate analyzes 61 biphasic insulin aspart 61 arterial thromboembolic events 61 pulmonary capillary wedge 61 ispinesib administered 61 SCr 61 hsCRP levels 61 #mg doses [002] 61 interquartile range 61 nonobese 61 comorbid disorders 61 systolic blood pressures 61 QTcF 61 tertiles 61 serum BDNF 61 mmol l 61 Ishak fibrosis score 61 symptom exacerbation 61 AST ALT 61 hypertensives 61 albumin excretion rate 61 prespecified 61 P = .# 61 Fasting plasma glucose 61 amisulpride 61 IFN alfa 61 VADT 61 CYP#D# genotype 61 antiandrogens 61 preoperative chemotherapy 61 CIMZIA ™ 61 adiponectin concentrations 61 HbA 1C 61 baseline A1C 61 serum CRP 61 dosing frequency 61 % CI #.#-#.# [007] 61 subclinical cardiovascular disease 61 clevidipine 61 PSADT 61 trials RCTs 61 extracapsular extension 61 confidence interval #.#-#.# 61 perioperatively 61 titrated glipizide 61 CIMZIA TM certolizumab pegol 61 paclitaxel eluting stents 61 caspofungin 61 HbA1c levels 61 Suicidal ideation 61 daily subcutaneous injections 61 ZOLINZA 61 psychiatric comorbidities 61 CHADS2 61 #mmHg [001] 61 spirometric 61 pharmacodynamics PD 61 serum sodium levels 61 erection hardness 61 noninferior 61 symptomatic VTE 61 troponin T 61 parous women 61 undergoing CABG 61 concomitant AEDs 61 FOLFOX4 61 antihypertensive therapy 61 virological response 61 ADCS ADL 61 CPAP adherence 61 iNO 61 de novo AML 61 affective psychoses 61 histological subtype 61 N telopeptide 61 Subgroup analyzes 61 HbA 1c 61 deep venous thromboses 61 DAS# remission 61 thiazides 61 extensive metabolizers 61 initiating antiretroviral therapy 61 MetS 61 serum uric acid 61 perimenopausal women 61 logistic regression analysis 61 beta adrenergic receptor 61 nonsignificant difference 61 everolimus eluting stents 61 overt hypothyroidism 61 serum calcium levels 61 teriflunomide 61 ß blockers 61 Tasigna prolongs 61 #mmHg [002] 61 dexmedetomidine 61 pentoxifylline 61 antiandrogen 61 anemia hemoglobin 61 antimuscarinic 60 Subgroup analysis 60 antiepileptics 60 glulisine 60 generalisable 60 divalproex sodium 60 Kaplan Meier curve 60 nonadherence 60 lumbar spine BMD 60 solifenacin 60 dose proportionality 60 recurrent VTE 60 carotid plaque 60 eosinophil count 60 HAQ DI 60 chlamydial infection 60 advanced adenoma 60 mammographic breast density 60 T2DM 60 left ventricular systolic 60 carotid intima media 60 tolterodine ER 60 Kaplan Meier analysis 60 locoregional recurrence 60 CANCIDAS 60 flutamide 60 pharmacokinetic parameters 60 inhaled iloprost 60 liver histology 60 NNRTI resistance 60 SHBG levels 60 glycosylated hemoglobin levels 60 EURIDIS 60 triglyceride concentration 60 racemic albuterol 60 suboptimal adherence 60 macroalbuminuria 60 SSRI SNRI 60 premorbid 60 binary restenosis 60 #ng/ml 60 antipsychotic prescribing 60 secondary efficacy endpoint 60 serum creatinine levels 60 salivary flow 60 BCG vaccinated 60 intravenous bisphosphonates 60 montelukast 60 Zemplar Capsules 60 ACEIs 60 intraobserver 60 aPTT 60 OADs 60 Univariate analysis 60 oral antidiabetes 60 BEXXAR Therapeutic Regimen 60 conjugated equine estrogen 60 serum TSH 60 tirofiban 60 prescribed antipsychotics 60 antiangiogenic therapy 60 IV bisphosphonates 60 creatinine clearance 60 elevated LDL cholesterol 60 posttransplant 60 operable breast cancer 60 nocturnal hypoglycaemia 60 Viral load 60 mild renal insufficiency 60 apolipoprotein B 60 nadroparin 60 iniparib 60 UPDRS scores 60 Lipitor #mg 60 uridine triacetate 60 seropositivity 60 hematological parameters 60 electrophysiologic 60 Non inferiority 60 antidiabetic drugs 60 Avandia Actos 60 bronchodilatory 60 Multivariate analyzes 60 NATRECOR R 60 selective modulator 60 affective psychosis 60 serum folate concentrations 60 Flu Cy 60 serum vitamin D 60 Calcium intake 60 depressive symptomatology 60 psychosocial functioning 60 RSV hospitalizations 60 null responder 60 tamoxifen Nolvadex ® 60 biochemical recurrence 60 postmenopausal hormones 60 pulmonary artery pressure 60 lispro 60 prostaglandin analogues 60 interferon alfa 2b 60 ± SEM 60 hypofractionated radiation 60 interobserver 60 protease inhibitor mutations 60 #mg dose [002] 60 insulin secretagogues 60 P ≤ 60 HIV uninfected 60 recurrent ischemia 60 canakinumab 60 heavily pretreated 60 antitumor effect 60 hyperphenylalaninemia HPA due 60 CLBP 60 acarbose 60 darunavir ritonavir 60 subgroup analyzes 60 virologic failure 60 microdose 60 XIENCE V demonstrated 60 pharmacokinetic characteristics 60 urinary cadmium 60 atypical neuroleptics 60 micafungin 60 nonpsychotic 60 galiximab 60 HIV coinfected 60 detrusor overactivity 60 fructose intolerant 60 angiographic restenosis 60 abnormal cytology 60 β blocker 60 highest tertile 60 APTIVUS r 60 serum PSA 60 mITT 60 aminotransferase levels 60 = #.#-#.# 60 progression TTP 60 postprandial blood glucose 60 APOE genotype 60 logistic regression models 60 GIK infusion 60 nasal symptom 60 cardiac autonomic 60 polyp recurrence 60 sotalol 60 bolus dose 60 sulphonylureas 60 dose clopidogrel 60 KRAS mutant tumors 60 nonfasting triglyceride levels 60 fluticasone salmeterol 60 anticholinergic agents 60 TEAEs 60 YMRS 60 pT3 60 viral kinetics 60 elevated IOP 60 riociguat 60 glomerular filtration rate 60 exhaled nitric oxide 60 neurocognitive functioning 60 gastric cardia 60 MAGE A3 ASCI 60 EDSS score 60 diastolic blood pressures 60 nonalcoholic steatohepatitis NASH 60 beta blocker therapy 60 hydroxyvitamin D concentrations 60 urodynamic parameters 60 elevated TSH 60 #mg dose [003] 60 paroxysmal AF 60 advanced adenomas 60 noncardiac 60 baseline LDH 60 CIN3 60 mean ± SEM 60 unfractionated heparin 60 extrapyramidal symptoms 60 acute mania 60 clinically meaningful improvement 60 mmHg diastolic 60 vasopressor 60 placebo p = 59 thyroid carcinoma 59 mm Hg diastolic 59 Celsentri Selzentry 59 CP CPPS 59 recurrent tonsillitis 59 lactate dehydrogenase 59 Secondary efficacy endpoints 59 diagnosing ADHD 59 statistically significant predictor 59 dobutamine 59 diuretic chlorthalidone 59 symptom severity 59 EDARBI 59 nonrandomized 59 postoperative morbidity 59 XR NTX 59 reactogenicity 59 euthymic 59 pre eclamptic 59 NATRECOR ® 59 AUC0 59 urate lowering therapy 59 rosuvastatin #mg 59 elevated hsCRP 59 cilostazol 59 elevated LDH 59 surrogate markers 59 dysfunctional voiding 59 doxorubicin docetaxel 59 ELBW infants 59 nmol l 59 azilsartan medoxomil 59 glycated hemoglobin 59 vitamin D inadequacy 59 serum parathyroid hormone 59 generalizability 59 antihypertensive medication 59 logistic regression model 59 bivariate analyzes 59 baseline CD4 59 primary aldosteronism 59 nonadherent 59 p = NS 59 prespecified secondary 59 serum GGT 59 symptomatic intracranial hemorrhage 59 sustained virological response 59 serum phosphorous 59 statistically significant 59 periprocedural 59 covariate 59 ATACAND 59 coinfected patients 59 dyslipidaemia 59 DLQI 59 interobserver reliability 59 TPV r 59 sociodemographic characteristics 59 reboxetine 59 EEG abnormalities 59 eNO 59 conventional antipsychotics 59 confidence interval CI 59 lymphocyte counts 59 nalbuphine 59 cTnT levels 59 Heavy menstrual bleeding 59 Pred Forte 59 TMP SMX 59 heFH 59 Fibromyalgia Impact Questionnaire 59 generalized anxiety disorder GAD 59 1mg dose 59 inert placebo 59 tacrolimus ointment 59 Serum creatinine 59 leukocyte counts 59 ARCALYST ® 59 olmesartan 59 Bonferroni correction 59 systolic function 59 triacylglycerol concentrations 59 odds ratios ORs 59 Symptom severity 59 serum bicarbonate 59 TNF alpha inhibitor 59 RAS blockers 59 ALLHAT 59 EpCAM expression 59 postoperative complication 59 BRCA mutation carriers 59 glargine 59 amoxicillin clavulanate 59 schizophreniform disorder 59 seroprotection 59 oral rivaroxaban 59 prolactin elevation 59 Neuropsychiatric Inventory NPI 59 oral antidiabetic medication 59 tarenflurbil 59 cortical atrophy 59 thiazide 59 salmeterol fluticasone propionate 59 statin monotherapy 59 T1DM 59 intratympanic 59 serum magnesium 59 completely resected 59 guanfacine extended release 59 levosimendan 59 CONCERTA ® 59 Triglyceride levels 59 prostate cancer CaP 59 CTEPH 59 BPS IC 59 undergoing coronary angiography 59 prednisone prednisolone 59 elevated triglyceride levels 59 carotid artery intima media 59 advanced neoplasia 59 IFN beta 59 Insulin sensitivity 59 analgesic efficacy 59 HBeAg seroconversion 59 creatinine levels 59 colorectal polyp 59 aldosterone antagonist 59 metabolic parameters 59 nmol liter 59 achieving PASI 59 hours postdose 59 bronchopulmonary dysplasia BPD 59 serum homocysteine 59 mRS 59 lacosamide 59 highly emetogenic 59 preserved ejection fraction 59 somatic symptom 59 inecalcitol 59 secondary efficacy endpoints 59 tenofovir emtricitabine 59 CCyR 59 carotid artery blockage 59 femoral neck BMD 59 glycated hemoglobin HbA1c 59 tipranavir ritonavir 59 NIHSS 59 myocardial infarctions MIs 59 strontium ranelate 59 buprenorphine implants 59 somatoform disorders 59 PNH patients 59 ER CHOP 59 8mg/kg 59 coronary calcification 59 subclinical hyperthyroidism 59 aminotransferase 59 Hb A1c 59 hemoglobin concentrations 59 non aspirin NSAIDs 59 colorectal liver metastases 59 Visual Analogue Scale VAS 59 intima media thickness IMT 59 experienced virologic failure 59 antipsychotic efficacy 59 FOSRENOL ® 59 newer atypical antipsychotics 59 endoscopic remission 59 urinary N telopeptide 59 urate levels 59 confidence intervals CIs 59 protein excretion 59 tranylcypromine 59 LNG IUS 59 impaired endothelial 59 tibolone 59 prolactin levels 59 pharmacokinetic interaction 59 PRADAXA #mg 59 comorbid anxiety 59 APOE ε4 59 intravenous RSD# 59 heterozygotes 59 cardiac repolarization 59 transaminase elevations 59 HSCT 59 pharmacodynamic parameters 59 active comparator 59 oral hypoglycemic agent 59 interindividual variability 59 EFFEXOR XR 59 blood Phe levels 59 subthreshold depression 59 neostigmine 59 #.#mmHg 59 abnormal lipid 59 atazanavir ritonavir 59 retrospective cohort 59 phytoestrogen intake 59 eculizumab therapy 59 prostate carcinoma 59 postoperative delirium 59 urodynamic 59 dose cohort 59 mg XP# 59 zoledronate 59 stratifying patients 59 antiresorptive 59 bioavailable testosterone 59 nocturnal hypoglycemia 59 PCWP 59 acetazolamide 59 clinico pathological 59 NRTI backbone 59 EBRT 59 mesalamine granules 59 leukopenia 59 coronary stenosis 59 serum phosphate 59 QTc 59 shorter telomere length 59 tolvaptan 59 ACTEMRA TM 59 tolterodine 59 macrolide antibiotic 59 NHANES III 59 mild renal impairment 59 unresectable HCC 59 anticoagulant warfarin 59 Postoperatively 59 nonsignificant 59 diastolic heart 59 serum aminotransferase levels 58 psychiatric morbidity 58 CrCl 58 colorectal adenomas 58 nitroprusside 58 hemodynamic parameters 58 Arranon 58 adenoma detection 58 nmol L. 58 external genital lesions 58 nondepressed 58 #OHD levels 58 guideline concordant 58 QIDS SR 58 OSAHS 58 chlorambucil 58 benazepril 58 preintervention 58 Preoperatively 58 QTc prolongation 58 conventional DMARDs 58 residual confounding 58 postoperative chemotherapy 58 hepatic fibrosis 58 comparator arm 58 urine albumin 58 meta analytic 58 nonischemic 58 lanthanum carbonate 58 K ras mutations 58 MDRD 58 Febrile neutropenia 58 antithymocyte globulin 58 LDL HDL 58 anti Xa 58 aromatase inhibitor therapy 58 idraparinux 58 triglyceride concentrations 58 rufinamide 58 mg/m2 dose 58 SGPT 58 transaminase levels 58 elevated creatinine 58 fumagillin nanoparticles 58 fibrinolytic therapy 58 ritonavir boosted 58 lowering blood glucose 58 systolic BP 58 agomelatine 58 Perforomist Inhalation Solution 58 cefazolin 58 nondemented 58 hepatic enzyme 58 platelet reactivity 58 reinfarction 58 lipid parameters 58 cystoscopic 58 trandolapril 58 radiochemotherapy 58 meta regression 58 mIU L 58 demonstrated clinically meaningful 58 recurrent glioblastoma multiforme 58 TDF FTC 58 AGILECT R 58 SNP rs# [002] 58 incomplete revascularization 58 p = .# [001] 58 isoflavone supplement 58 intracranial hemorrhage ICH 58 calcium antagonists 58 mCRPC 58 prolonged QT interval 58 plasma selenium 58 rtPA 58 Zevalin consolidation 58 rhinoconjunctivitis 58 neurodevelopmental outcome 58 Platelet counts 58 UKPDS 58 #OHD 58 pharmacologically active isomer 58 Cmax 58 low dose Iluvien 58 lipid lowering drugs 58 biologic DMARDs 58 lymphocyte count 58 Stent thrombosis 58 atopic asthma 58 ALB # 58 Montgomery Åsberg Depression 58 ibandronate 58 peak plasma concentrations 58 bovine thrombin 58 biochemical relapse 58 serum triglyceride 58 T2 lesions 58 prescribed statins 58 chemoradiation therapy 58 renal cysts 58 lipoprotein profiles 58 sociodemographic factors 58 folate concentrations 58 bronchial hyperresponsiveness 58 LV ejection fraction 58 pegaptanib 58 overactive bladder symptoms 58 DHEA supplementation 58 clinically meaningful reductions 58 dysmenorrhoea 58 serotonin synthesis 58 quetiapine 58 angiotensin converting enzyme inhibitors 58 pharmacodynamic PD 58 Plasma concentrations 58 hepatitis C genotype 58 subcutaneous insulin 58 virologic response 58 acromegalic patients 58 fractional anisotropy 58 pg ml 58 pretest probability 58 5-FU/LV 58 serum cortisol 58 noncardiovascular mortality 58 fluvastatin 58 mcg albinterferon alfa 2b 58 SCIg 58 pmol L 58 stavudine d4T 58 SSRI antidepressant 58 GI toxicity 58 dose dependently 58 glycosylated hemoglobin HbA1c 58 RE LY ® 58 ovulatory cycles 58 vaginal progesterone gel 58 fasting glucose levels 58 hypercholesterolaemia 58 antidepressant paroxetine 58 dapagliflozin plus 58 intelligence quotient IQ 58 mycophenolic acid 58 plasma cortisol 58 anastomotic leak 58 chloride secretion 58 H. pylori eradication 58 angiographic outcomes 58 biopsy Gleason 58 reduce serum phosphate 58 bosentan 58 aldosterone antagonists 58 neuroleptic 58 adjunctive ABILIFY 58 ejection fraction EF 58 citalopram 58 methotrexate therapy 58 DAPT 58 oral olanzapine 58 recurrent UTI 58 MS relapses 58 #.#ng/ml 58 plasma glucose concentrations 58 multivariate regression 58 valvulopathy 58 plasma glucose levels 58 oncologic outcomes 58 clinicopathological features 58 DULERA 58 docetaxel pretreated 58 rHuEPO 58 Eligen R B# 58 HF ACTION 58 ECOG PS 58 #mg/day [002] 58 serum potassium 58 #.#mg/dL 58 umol L 58 NAbs 58 sodium nitroprusside 58 taxane refractory 58 selegiline 58 multivariate Cox 58 SERCA2a 58 insulin glulisine 58 STEP BD 58 antihypertensive medications 58 POAG 58 dietary calcium intake 58 dopamine partial agonist 58 follicular lymphoma FL 58 NMDA antagonists 58 inhaled budesonide 58 coronary stenoses 58 pulmonary arterial 58 mm Hg systolic 58 achieve sustained virologic 58 Ceplene/IL-2 58 GERD symptom 58 lesional 58 LHRH agonists 58 mg/m2 cohort 58 syndromal 58 mcg QD 58 Secondary endpoints 58 Charlson comorbidity index 58 labetalol 58 squamous histology 58 hypoglycemic episodes 58 serum testosterone 58 pharmacologic treatments 58 dietary folate 58 lifetime abstainers 58 virological failure 58 protease inhibitor PI 58 Sumatriptan OS 58 lymphocytosis 58 oral FTY# 58 bivariate 58 ertapenem 58 thromboembolic complications 58 surrogate endpoint 58 revascularizations 58 LEXIVA r 58 loop diuretics 58 ovarian carcinoma 58 hyper IgE syndrome 58 induced akathisia 58 RE LY trial 58 ancrod 58 LVSD